Analyzing ImmuCell (ICCC) & Myriad Genetics (MYGN)

Share on StockTwits

ImmuCell (NASDAQ:ICCC) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Risk & Volatility

ImmuCell has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500.

Insider and Institutional Ownership

14.0% of ImmuCell shares are owned by institutional investors. Comparatively, 99.8% of Myriad Genetics shares are owned by institutional investors. 17.7% of ImmuCell shares are owned by insiders. Comparatively, 5.8% of Myriad Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares ImmuCell and Myriad Genetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ImmuCell -13.09% -3.89% -2.69%
Myriad Genetics 7.07% 10.07% 7.62%

Analyst Recommendations

This is a summary of current ratings and price targets for ImmuCell and Myriad Genetics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmuCell 0 0 0 0 N/A
Myriad Genetics 2 3 4 0 2.22

Myriad Genetics has a consensus price target of $41.11, indicating a potential upside of 30.14%. Given Myriad Genetics’ higher possible upside, analysts clearly believe Myriad Genetics is more favorable than ImmuCell.

Valuation and Earnings

This table compares ImmuCell and Myriad Genetics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmuCell $10.43 million 3.78 -$160,000.00 N/A N/A
Myriad Genetics $772.60 million 3.06 $131.10 million $1.20 26.33

Myriad Genetics has higher revenue and earnings than ImmuCell.

Summary

Myriad Genetics beats ImmuCell on 8 of the 11 factors compared between the two stocks.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company primarily offers First Defense, an orally delivered scours preventive product for newborn calves. It also provides California Mastitis Test, which is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing purified Nisin treatment for subclinical mastitis in lactating dairy cows; and selling various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to animal health distributors, fleet stores, and direct to farms. The company was founded in 1982 and is headquartered in Portland, Maine.

Myriad Genetics Company Profile

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency. In addition, Myriad Genetics, Inc. offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply